source
- EyePoint cuts half its staff and ends wet AMD trials after second Phase 3 failure, pivots to diabetic macular edemaEyePoint said it is launching a strategic review after its investigational drug duravyu failed another Phase 3 study in wet age‑related macular degeneration. The company reported that the top‑line…
- China proposes new limits on foreign biotech acquisitions to protect domestic drug developmentChina is drafting new rules that would restrict foreign companies from acquiring Chinese biotech assets deemed critical to the nation's drug development sector. The proposal aims to keep control o…